BA-3071 is under clinical development by BioAtla and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BA-3071’s likelihood of approval (LoA) and phase transition for Bladder Cancer took place on 13 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 13 Sep 2022 increased BA-3071’s LoA and PTSR for Gastric Cancer, increased LoA and PTSR for Hepatocellular Carcinoma, increased LoA and PTSR for Melanoma, increased LoA and PTSR for Non-Small Cell Lung Cancer, increased LoA and PTSR for Renal Cell Carcinoma, increased LoA and PTSR for Small-Cell Lung Cancer, and increased LoA and PTSR for Cervical Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BA-3071 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BA-3071 overview

BA-3071 is under development for non-small cell lung cancer, colon adenocarcinoma, small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, bladder, gastric, cervical and melanoma. It acts as checkpoint inhibitor by targeting against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It is based on conditionally active biologics (CAB) that optimizes antibodies to be activated and/or inactivated at defined physiological conditions.

BioAtla overview

BioAtla is a clinical-stage biopharmaceutical company that focused on on developing antibody-based therapeutics for the treatment of solid tumor cancer. The company product candidate includes BA3011, BA3021 and BA3071, BA3182, BA3142, BA3311, BA336 and BA3151. BioAtla lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is protein kinase receptor. Its BA3021 is developing a CAB antibody drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2), BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. The company offers laboratories in the US and China. BioAtla is headquartered in San Diego, California, the US.

Quick View BA-3071 LOA Data

Report Segments
  • Innovator
Drug Name
  • BA-3071
Administration Pathway
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: BioAtla
  • Originator: BioAtla
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.